Latest Conference Articles

July 31st 2020, 9:45pm

International Congress on the Future of Breast Cancer West

Joyce A. O'Shaughnessy, MD, discusses the importance of research regarding the application of DNA repair deficiency in breast cancer, even though it's still in early stages.

July 31st 2020, 9:32pm

School of Nursing Oncology

In order to achieve health equity for patients with cancer, physicians must first understand the root cause of heath disparities, many of which may be invisible.

July 31st 2020, 9:30pm

School of Nursing Oncology

Chasity M. Washington, MPH, CHES, discusses ways to mitigate racial disparities in oncology.

July 31st 2020, 9:30pm

School of Nursing Oncology

Beth Sandy, MSN, CRNP, discusses the evolving treatment landscape in small cell lung cancer.

July 31st 2020, 9:10pm

School of Nursing Oncology

One of the most important tasks that oncology nurses face is ensuring that patients are taking their medications consistently and correctly, and that adverse events are properly managed—specifically in those patients with breast cancer.

July 31st 2020, 7:00pm

International Congress on the Future of Breast Cancer West

Debu Tripathy, MD, discusses genomically guided therapy in breast cancer.

July 27th 2020, 10:24pm

International Lung Cancer Congress

Paul A. Bunn, Jr, MD, highlights encouraging data with fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.

July 27th 2020, 9:42pm

International Lung Cancer Congress

Anne Chiang, MD, PhD, discusses unanswered questions with immunotherapy in non–small cell lung cancer.

July 27th 2020, 9:41pm

International Lung Cancer Congress

Although platinum-based chemotherapy given concurrently with a PD-L1 inhibitor has become the standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer, investigators have found that maintenance immunotherapy and combination strategies have fallen short of expectations.

July 27th 2020, 9:30pm

International Lung Cancer Congress

The introduction of tyrosine kinase inhibitor therapy earlier in the treatment timeline for patients with EGFR-mutant non–small cell lung cancer holds the promise of improving overall survival for this patient population.

July 27th 2020, 7:14pm

International Lung Cancer Congress

David R. Gandara, MD, discusses the current state of tumor mutational burden in lung cancer, ongoing research further examining the utility of this biomarker, and challenges to address with future research.

July 24th 2020, 9:40pm

International Lung Cancer Congress

Paul Baas, MD, PhD, discusses recent updates in immuno-oncology within the field of mesothelioma.

July 24th 2020, 9:35pm

International Lung Cancer Congress

Benjamin P. Levy, MD, discusses the efficacy of crizotinib (Xalkori) versus entrectinib in ROS1-rearranged lung cancer.

July 24th 2020, 6:58pm

International Lung Cancer Congress

Charu Aggarwal, MD, MPH, discusses the current state of treatment for patients with ALK-positive non–small cell lung cancer, the utility of liquid biopsy, and remaining questions that need to be addressed in the space.

July 24th 2020, 6:30pm

International Lung Cancer Congress

Although antibody-drug conjugates have yet to receive regulatory approval in the lung cancer space, several emerging agents are showing early promise in clinical trials.

July 24th 2020, 5:15pm

International Lung Cancer Congress

Clinical data shows that the TRK inhibitors entrectinib and larotrectinib induce high response rates with favorable toxicity profiles and central nervous system penetration, and are a viable treatment option for patients with advanced TRK fusion-positive cancers.

July 23rd 2020, 10:35pm

International Lung Cancer Congress

Ignacio I. Wistuba, MD, discusses the clinical importance of histological subtyping of lung cancer and additional parameters such as driver alterations, alternative methods for molecular testing, and immunotherapy-related biomarkers have strengthened the diagnostic and treatment paradigms in lung cancer.

July 23rd 2020, 10:18pm

International Lung Cancer Congress

In non–small cell lung cancer, single cell analytics, genome editing, and next-generation animal models represent just some of the modern modalities advancing translational research.

July 23rd 2020, 9:54pm

International Lung Cancer Congress

The disease-free survival benefit observed with the third-generation EGFR TKI osimertinib as an adjuvant treatment in patients with EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA trial is striking.

July 23rd 2020, 9:45pm

International Lung Cancer Congress

Charu Aggarwal, MD, MPH, discusses emerging treatment approaches in ALK-positive non–small cell lung cancer.